Search

everythinglearnresearchcommunity

for

Search:↓

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Some drugs can cause skin reactions, which may improve when the drug is stopped, and rapid diagnosis and stopping the drug is crucial.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

The "color-transition sign" helps tell apart alopecia areata incognita from telogen effluvium by looking at hair color changes.

Etanercept, a psoriasis treatment, caused hair loss in a patient.

Mast cells play a significant role in hair loss conditions like male pattern hair loss and alopecia areata.

People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Certain drugs increase calcium levels in cancer cells by triggering internal calcium release.

Targeting immune tolerance issues in Alopecia Areata could restore hair growth and maintain remission.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Blocking interferon-gamma might help treat various autoimmune diseases.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

A horse with severe hair loss was diagnosed with alopecia areata and a yeast infection.

JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.

CD2 might be a new treatment target for patchy alopecia areata.

Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.

The document concludes that autoimmune skin disorders are treated with corticosteroids and immunosuppressive drugs.

New cytokine-targeted therapies show promise for treating alopecia areata.

Certain gene variations may increase the risk and severity of alopecia areata.

Leflunomide is more likely to help treat alopecia areata than cause it.

The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.

IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.

Different types of fibroblasts play specific roles in wound healing and cancer, which could help improve treatments.

PPAR-γ may be a key target for treating alopecia areata and other skin conditions.

COVID-19 may trigger or worsen rapid hair loss in alopecia areata.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.